Infinity Pharmaceuticals Inc. (INFI): Infinity Pharmaceuticals Presents A ... Seeking Alpha This recommendation was based on a predefined interim analysis showing highly statistically significant efficacy for the primary endpoint of progression-free survival in patients receiving idelalisib plus rituximab compared to those receiving rituximab ... |
